Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canrenoate potassium for COVID-19-associated pulmonary fibrosis
NCT04912011Phase 4Unknown
- Sponsor
- Pomeranian Medical University in Szczecin
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of potassium canrenoate in pulmonary fibrosis (PF) and COVID-19 pneumonia, sponsored by Pomeranian Medical University in Szczecin. Primary endpoint: Mechanical ventilation at 30 days. Status: unknown.
02
Drugs
potassium canrenoate
03
Conditions
pulmonary fibrosis (PF)COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04912011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912011.